Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study

Abstract

ObjectiveA previous study demonstrated that non-anthracycline-containing docetaxel plus cyclophosphamide (TC) regimen was inferior to docetaxel, anthracycline and cyclophosphamide (TAC) in neoadjuvant treatment of triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2-(HER2)-positive breast cancer in a short-term follow-up. Herein, long-term follow-up survival outcomes have been investigated.MethodsTNBC or HER2-positive patients were randomized to receive 6 cycles of TC or TAC neoadjuvant treatment. The primary endpoint was pathological complete remission (pCR). Secondary endpoints included clinical response rate, event-free survival (EFS), and overall survival (OS).ResultsA cohort of 96 patients consisted of 45 in TC and 51 in TAC arm. With a median follow-up period of 53 (range, 8–76) months, the patients achieving pCR post neoadjuvant chemotherapy exhibited superior EFS and OS than patients without pCR (P<0.05). TAC treatment resulted in consistently better EFS than TC treatment: the estimated 5-year EFS was 66.1% vs. 29.8% (P=0.002). Moreover, the estimated 5-year OS was also in favor of TAC: 88.4% vs. 51.6% (P<0.001). Multivariable analysis demonstrated that the treatment regimen was an independent prognostic factor, and patients treated with TAC had a superior EFS [hazard ratio (HR), 0.48; 95% confidence interval (95% CI), 0.26–0.90; P=0.021] and OS (HR, 0.20; 95% CI, 0.08–0.60; P=0.003). ConclusionsThe updated long-term follow-up data demonstrated a sustained benefit in EFS and OS from anthracycline-containing TAC treatment, indicating that anthracycline is an essential and effective drug in this clinical trial.

VEGF-A/Neuropilin 1 Pathway Confers Cancer Stemness via Activating Wnt/β-Catenin Axis in Breast Cancer Cells

“…Although endocrine therapy, targeting therapy and chemotherapeutics have greatly improved the overall survival of breast cancer patients, the drug resistance is the main clinical problem [24]. Recent studies have demonstrated that CSCs are the major factor contributing to drug resistance because of their relatively quiescent or dormant state [25].…”

Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells

“…Nowadays, esophageal cancer has been identified as the sixth most common cause of cancer-related death all over the world, and more than one third of esophageal cases are diagnosed at advanced stage [1]. Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of this cancer in China [2]. Although there are three major treatment modalities for esophageal cancer including surgery, radiotherapy and chemotherapy, radiotherapy is widely applied to the patients who are not candidates for operations [3–5].…”

Time trends of esophageal and gastric cancer mortality in China, 1991–2009: an age-period-cohort analysis

“…As a high-risk area for digestive cancers, China was estimated to suffer 375,000 esophageal cancer deaths and 498,000 gastric cancer deaths in 2015, which together represented 31.0% of all cancer deaths 2 . In the Chinese cancer profile, gastric cancer and esophageal cancer ranked third and fourth in cancer mortality in 2012, with mortalities reaching as high as 22.04 and 15.58 per 100,000, respectively 3 .…”